Bluebird Bio reported $66.48M in Cash and Equivalent for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Agios Pharmaceuticals AGIO:US USD 139.26M 16.81M
Alnylam Pharmaceuticals ALNY:US USD 866.39M 206.83M
Amgen AMGN:US USD 9.3B 197M
Arrowhead Research ARWR:US USD 202.25M 94.24M
Avrobio Inc AVRO:US USD 115.97M 16.44M
Biogen BIIB:US USD 3.42B 256.3M
Biomarin Pharmaceutical BMRN:US USD 724.53M 36.98M
Bluebird Bio BLUE:US USD 66.48M 15.02M
Gilead Sciences GILD:US USD 7.63B 2.93B
Immunogen IMGN:US USD 275.14M 34.37M
Intercept Pharmaceuticals ICPT:US USD 50.52M 62.68M
Mirati Therapeutics MRTX:US USD 182.23M 8.69M
Moderna Inc MRNA:US USD 3.2B 178M
Nektar Therapeutics NKTR:US USD 88.23M 17.53M
Novartis NOVN:VX USD 7.52B 1.21B
Ptc Therapeutics PTCT:US USD 279.83M 175.41M
Regeneron Pharmaceuticals REGN:US USD 14.33B 10.84B
Sangamo Biosciences SGMO:US USD 100.44M 5.87M
Sarepta Therapeutics SRPT:US USD 966.78M 71.85M
Seattle Genetics SGEN:US USD 319.94M 42.66M
Ultragenyx Pharmaceutical RARE:US USD 132.94M 258.71M
Vertex Pharmaceuticals VRTX:US USD 10.78B 1.61B
YTE INCY:US USD 2.95B 260.8M